Bladder Cancer Immunotherapy: AstraZeneca’s Imfinzi Gets 2nd FDA Nod

Bladder cancer immunotherapy from AstraZeneca received its second FDA approval for resectable muscle-invasive disease. The Silicon Review reports on the practice-changing NIAGARA trial results.

AstraZeneca's bladder cancer immunotherapy Imfinzi has received its second regulatory approval for treating resectable muscle-invasive bladder cancer (MIBC) following positive results from the Phase 3 NIAGARA trial. The approval allows the bladder cancer immunotherapy to be used before and after surgery in patients with resectable MIBC.

The bladder cancer immunotherapy is now approved in the perioperative setting, meaning Imfinzi can be administered both as neoadjuvant therapy before bladder removal surgery and as adjuvant therapy after surgery. This expands the bladder cancer immunotherapy's reach beyond previously approved advanced or metastatic settings.

The NIAGARA trial evaluated the bladder cancer immunotherapy in combination with neoadjuvant chemotherapy before radical cystectomy. The bladder cancer immunotherapy demonstrated statistically significant improvements in event-free survival and overall survival compared to chemotherapy alone.

Approximately 600,000 people are diagnosed with bladder cancer globally each year, with about one-quarter presenting with muscle-invasive disease. The resectable MIBC population represents a significant expansion opportunity for the bladder cancer immunotherapy.

AstraZeneca gained its first bladder cancer approval for Imfinzi in May 2026 for locally advanced or metastatic urothelial cancer. The second approval makes Imfinzi the first bladder cancer immunotherapy approved in the perioperative setting for resectable MIBC.

As AstraZeneca's bladder cancer immunotherapy Imfinzi gains its second FDA approval, The Silicon Review examines how the NIAGARA trial could transform treatment paradigms for patients with resectable muscle-invasive disease.

Q: What is the new indication for AstraZeneca's bladder cancer immunotherapy?
A: The bladder cancer immunotherapy Imfinzi is now approved for resectable muscle-invasive bladder cancer before and after surgery, based on the Phase 3 NIAGARA trial.

Q: How does this bladder cancer immunotherapy work?
A: The bladder cancer immunotherapy Imfinzi is a PD-L1 blocking antibody that helps the immune system recognize and attack cancer cells. In the perioperative setting, it is given before and after bladder removal surgery.

Q: What did the NIAGARA trial show for this bladder cancer immunotherapy?
A: The NIAGARA trial showed that the bladder cancer immunotherapy Imfinzi plus chemotherapy significantly improved event-free survival and overall survival compared to chemotherapy alone.

Q: Is this the first approval for this bladder cancer immunotherapy?
A: No. This is the second approval for the bladder cancer immunotherapy. The first approval in May 2026 was for locally advanced or metastatic urothelial cancer.

Q: How many people are diagnosed with bladder cancer globally each year?
A: Approximately 600,000 people are diagnosed with bladder cancer globally each year, with about one-quarter presenting with muscle-invasive disease.

Q: When will the full NIAGARA trial results for this bladder cancer immunotherapy are presented?
A: The full NIAGARA dataset will be presented at the 2026 American Society of Clinical Oncology annual meeting in June.